Boston Scientific Corporation (SWX:BSX)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 51.20B -54.8% |
| Revenue (ttm) | 16.96B +13.5% |
| Net Income | 2.97B +46.7% |
| EPS | 1.99 +46.9% |
| Shares Out | n/a |
| PE Ratio | 17.25 |
| Forward PE | 12.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 36.05 |
| Day's Range | n/a |
| 52-Week Range | 34.54 - 80.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its A...
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the ...
Boston Scientific Transcript: Wells Fargo 21st Annual Healthcare Conference
Operations have fully recovered from a global cyber attack, but financial guidance for Q3 and the full year will not be met. WATCHMAN faces market headwinds and new competition, while EP growth moderates amid strong product launches planned for 2027. The Penumbra acquisition and new platforms in cardiovascular and urology are expected to drive future growth.
Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific Won't Meet Guidance Due to Cyberattack
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket ...
Boston Scientific says cyberattack likely to hurt 2026 sales, profit
Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 ...
Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'
Boston Scientific's stock is sliding in the wake of a major cyberattack, adding to its recent woes.
Boston Scientific Stock Price Drops After Cyberattack Triggers Global Outage
The medical-device maker said order processing and shipping have been disrupted.
Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption' to its operations
A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday, the latest healthtech g...
Boston Scientific Stock Is Falling as Cyberattack Puts More Strain on the Medical Device Maker
Boston Scientific stock falls as the medical device maker announces the latest batch of bad news for the company.
Medical device maker Boston Scientific is being hit by a cyber attack. The shares are falling
Boston Scientific was hit with a cyberattack that is affecting its operations, the company said Wednesday in an SEC filing. The attack is continuing to disrupt the company's ability to ship products, ...
Boston Scientific hit by cyberattack, global operations affected
Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.
Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Boston Scientific Earnings Call Transcript: Q2 2026
Q2 2026 saw 7% organic sales growth and 15% adjusted EPS growth, exceeding guidance. Full-year 2026 outlook was revised down due to WATCHMAN and EP headwinds, with organic revenue now expected to grow 5%-6% and adjusted EPS 7%-8%. Restructuring and new launches are set to drive recovery by 2028.
Boston Scientific Slides: Q2 2026
Boston Scientific has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Boston Scientific Earnings release: Q2 2026
Boston Scientific released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Boston Scientific Quarterly report: Q2 2026
Boston Scientific has published its Q2 2026 quarterly earnings report on July 29, 2026.
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
Boston Scientific trims annual profit forecast on softer Watchman device demand
Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Boston Scientific announces results for second quarter 2026
MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported b...
Boston Scientific unveils new restructuring plan, expects job cuts
Boston Scientific's board has approved a new company-wide restructuring plan aimed at cutting costs and to better position the company for future growth, the medical device maker said in a regulator...
Belo Sun Announces Management Transition
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Vol...
Belo Sun Announces Corporate Update
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...